Dissociation of Gemcitabine Sensitivity and Protein Kinase B Signaling in Pancreatic Ductal Adenocarcinoma Models
Authors:
- Ming-Sound TsaoMTMing-Sound Tsao
- Pinjiang CaoPCPinjiang Cao
- David William HedleyDHDavid William Hedley
- 1 October 2007
- journal article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 35 (3) , e16-e26
Abstract
To understand the impact of protein kinase B (PKB; Akt) signaling on growth and protection from apoptosis in pancreatic ductal adenocarcinoma models demonstrating differences in PKB activity. Gemcitabine sensitivity was investigated in a panel of cell lines, characterized by differences in levels of activated PKB. Suppression of PKB activity was achieved with an inhibitor of phosphatidylinositol 3-kinase (wortmannin) and silencing RNA. Enhanced gemcitabine (2',2'-difluoro-2'-deoxycytidine)-induced cytotoxicity in vitro was achieved with suppression of high PKB activity with wortmannin in BxPC-3, PK-1, and PK-8 cells and silencing RNA targeted to total PKB, rather than PKBbeta, in PANC-1 cells. Opposite to gemcitabine sensitivity levels in vitro, the growth of PANC-1 xenografts was inhibited with gemcitabine treatment, whereas BxPC-3 became drug resistant. Monolayer cell cultures reestablished from solid tumors behaved similarly to original cultures, suggesting that the tumor microenvironment has a critical role in determining drug sensitivity. A comparison of transcript profiles of the models indicated that PKB signaling might be modulated by a number of pathways responsive to the tumor hypoxia microenvironment. These results suggested that gemcitabine efficacy involving the PKB pathway depends on PKB activity, its mechanisms of enhanced activity, as well as its function in a signaling network.Keywords
This publication has 47 references indexed in Scilit:
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005
- Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survivalOncogene, 2005
- In vitro Modeling of Human Pancreatic Duct Epithelial Cell Transformation Defines Gene Expression Changes Induced by K-ras Oncogenic Activation in Pancreatic CarcinogenesisCancer Research, 2005
- siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity1Journal of the American College of Surgeons, 2004
- Thioredoxin Is Downstream of Smad7 in a Pathway That Promotes Growth and Suppresses Cisplatin-Induced Apoptosis in Pancreatic CancerCancer Research, 2004
- A Serial Analysis of Gene Expression (SAGE) Database Analysis of ChemosensitivityCancer Research, 2004
- Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria‐mediated apoptosisInternational Journal of Cancer, 2003
- Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancerInternational Journal of Cancer, 1999
- Amplification and overexpression of theAKT2 oncogene in a subset of human pancreatic ductal adenocarcinomasMolecular Carcinogenesis, 1998
- Establishment of six human pancreatic cancer cell lines and their sensitivities to anti-tumor drugs.The Tohoku Journal of Experimental Medicine, 1986